Genenta Science Spa (GNTA) Stock News

Genenta (Nasdaq: GNTA), evolving into Saentra Forge, signed a binding offer to fund Italian aerospace manufacturer Sòphia High Tech via two reserved capital increases for a potential controlling stake upon performance milestones. Genenta expects to fund EUR 6.0 million in two tranches to scale production, technology, and commercial reach; the deal is subject to due diligence, approvals, and definitive documentation.

Sòphia HT is profitable, forecasts EBITDA growth for 2026–2027, employs 40+ engineers and has completed over 530 projects serving ESA, AVIO, Leonardo, MBDA and others.

Genenta (Nasdaq: GNTA) announced on March 24, 2026 that it is evolving into Saentra Forge, an industrial consolidator targeting biotech, defense, aerospace and national-security technologies. The company said it is working with DC Advisory to explore collaboration opportunities for its original biotechnology platform, but has no active discussions regarding Temferon to date.

Management emphasized continued pursuit of partners given prior preliminary clinical data, founder-scientists' ongoing shareholdings, and a strategic shift toward selective acquisitions and industrial aggregation.

Genenta (Nasdaq: GNTA), evolving to Saentra Forge (Nasdaq: SAEN), announced on March 13, 2026 that CEO Pierluigi Paracchi was appointed by the Italian government to the Board of Guarantors of the Italian Academy at Columbia University.

The appointment, conferred by Deputy Prime Minister Antonio Tajani and transmitted by Ambassador Marco Peronaci, places the CEO on a 12‑member board that supports the Academy’s research and cultural exchange activities.

Genenta Science (Nasdaq: GNTA), transforming into Saentra Forge (Nasdaq: SAEN), announced appointment of Paolo Salvato to the Board of ATC, marking its first entry into defense manufacturing, and confirmed ongoing evaluation of majority-control acquisitions in regulated national-security sectors. Nature Medicine accepted a manuscript reporting key clinical findings from the company’s Glioblastoma multiforme trial, with publication expected in the coming weeks.

Management said it is prioritizing profitable, majority-controlled industrial scale-ups and evaluating biotech partnerships to reduce capital needs for registrational studies, while retaining flexibility to access U.S. public markets subject to market and regulatory conditions.

Genenta Science (Nasdaq: GNTA) is transforming into an industrial consolidator focused on biotech, defense, aerospace, and national security and intends to adopt the new name Saentra Forge S.p.A with a planned Nasdaq ticker of SAEN. The company has begun execution by funding a staged, performance-based acquisition of ATC, a precision weapons manufacturer, with total funding expected of EUR 5.1 million. ATC forecasts ~€4.0M revenue and >€2.0M EBITDA in 2026, rising to ~€9.0M and roughly double EBITDA in 2027. The Praexidia Foundation joined as a long-term shareholder under a five-year lock-up. The company expects cash and marketable securities of ~$33M at Dec 31, 2025 and has engaged DC Advisory for biotech partnering.

Genenta Science (Nasdaq: GNTA) updated ownership details for CEO and co-founder Pierluigi Paracchi as of December 19, 2025. The company reports Mr. Paracchi has acquired 30,000 ADSs over time via open-market purchases and has not reported any sales in SEC filings. In total, he owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta’s outstanding share capital as calculated under SEC rules.

The disclosure indicates founder insider accumulation and a sizable single-holder stake that investors may consider when evaluating free float and insider alignment.

Genenta Science (Nasdaq: GNTA) reported a November 21, 2025 data cut from its TEM-GBM study in newly diagnosed glioblastoma patients with unmethylated MGMT. As of the cut, 25 patients treated with Temferon showed 44% 18‑month survival (vs 38% in April), a 2‑year survival of 29%, and median overall survival of 17 months, all consistent with prior updates. Historical uMGMT benchmarks cited: ~14% two‑year survival and 13–15 months median OS. One patient reached 39 months post‑surgery without intervening therapy and completed a 3.5‑year follow‑up. Findings include preliminary immune evidence that bone‑marrow‑derived myeloid cells can reach tumor tissue to deliver payloads. The company held approximately $30 million in cash and short‑term investments as of November 1, 2025.

Genenta Science (Nasdaq: GNTA) announced a registered direct offering to sell 4,285,715 ADSs at $3.50 per ADS for gross proceeds of approximately $15.0 million, before fees and expenses. Maxim Group is lead placement agent and Rodman & Renshaw is co-placement agent. Genenta intends to use net proceeds for working capital and general corporate purposes. The offering is expected to close on or about October 28, 2025, subject to customary closing conditions and a prospectus supplement to be filed under its effective Form F-3 registration.

Genenta Science (Nasdaq: GNTA) and ANEMOCYTE announced an expanded strategic collaboration on an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform, dated October 24, 2025. The agreement builds on an existing partnership and makes Genenta's clinically validated LVV Plasmid DNA platform, originating from research by Professor Luigi Naldini, available to ANEMOCYTE and its clients.

The collaboration aims to supply top-quality plasmid DNA across R&D to GMP grade and from preclinical to commercial stages, supporting scalable advanced therapy program development and broadening ANEMOCYTE's offering to customers.